Business
Entheon Issues Incentive Stock Options
Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that the Company has granted options to purchase up to an aggregate 40,000 common shares in the Company (the "Options") to certain directors of the Company. The Options are exercisable at $0.145 per share for a period of two years from the date of grant. The Options have been granted under ...
About this update from Entheon Biomedical Corp.
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that the Company has granted options to purchase up to an aggregate 40,000 common shares in the Company (the "Options") to certain directors of the Company. The Options are exercisable at $0.145 per share for a period of two years from the date of grant. The Options have been granted under and are governed by the terms of the Company's incentive stock option plan approved by the Company's shareholders at its annual general meeting held on December 16, 2024.","length":666,"tagName":"p"},{"type":"text","content":"About Entheon Biomedical Corp.","length":30,"tagName":"p"},{"type":"text","content":"Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.","length":121,"tagName":"p"},{"type":"text","content":"On Behalf of the Board of Directors,Timothy Ko, CEO, President and Director","length":76,"tagName":"p"},{"type":"text","content":"For more information, please contact the Company at: Entheon Biomedical Corp. Timothy Ko, CEO 1 (604) [email protected] https://entheonbiomedical.com","length":174,"tagName":"p"},{"type":"text","content":"To view the source version of this press release, please visit https://www.newsfilecorp.com/release/246827","length":106,"tagName":"p"}]